Swiss player ready for reduced cost resveratrol launch
10-year-old Swiss biotech firm Evolva has completed the resveratrol manufacturing cost-reduction programme it embarked on for the antioxidant nearly two years ago when it bought defunct Fluxome’s business for €550,000.